-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下：Generac公佈了強勁的第一季業績，淨銷售額同比增長12%至10.6億美元，主要得益於其商業和工業業務板塊28%的激增，而數據中心需求的加速增長是推動這一增長的主要動力。同時，由於家用備用發電機價格上漲被銷售下降所抵消，住宅業務銷售額僅成長1%。調整後EBITDA利潤率從15.9%顯著提升至18.3%，這反映了商業和工業業務銷售成長帶來的強勁營運槓桿效應，以及重組後的住宅業務的大幅成本節約。我們認為，強勁的商業和工業業務成長勢頭以及不斷增長的訂單積壓是支撐我們積極投資邏輯的關鍵催化劑。受第一季業績優異和商業和工業業務訂單積壓快速增長的提振，管理層上調了全年業績預期。我們將GNRC未來12個月的目標股價從235美元上調至275美元，本益比為25.7倍，基於我們修訂後的2027年每股收益預期10.70美元（此前預期為10.42美元），該估值接近GNRC五年平均市盈率，但考慮到其盈利性，低於電氣設備同行的平均水平。此外，我們將2026年每股盈餘預期從8.10美元上調至8.56美元。
Related Articles
Research
Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.
$VRTX
Asia
ALS Flags Unauthorized Access to Its IT Systems
ALS (ASX:ALQ) reported a cyber incident involving unauthorized third-party access to some of its information technology (IT) systems, temporarily disrupting parts of its operations, according to a Tuesday Australian bourse filing.The company, with support from external cybersecurity specialists, has implemented containment measures in line with incident response procedures, restoring most operations while continuing targeted remediation in affected areas, per the filing.The company has informed the Australian Cyber Security Center and is investigating the full extent of the breach and its potential data impact, the filing added.
$ASX:ALQ
Asia
Dexus Secures JV With Boral for Major Ravenhall Logistics Precinct in Melbourne
Dexus (ASX:DXS) has entered a joint venture (JV) with Boral (ASX:BLD) to develop a large-scale logistics precinct in Ravenhall, Melbourne's western corridor, spanning 630 hectares and targeting up to 2.5 million square meters of lettable space, subject to rezoning and regulatory approvals, according to a Tuesday Australian bourse filing.The JV structure gives the company and other capital partners a combined 50% stake, while Boral retains the remaining 50%, with the project developed in staged superlots and supported by substantial third-party capital to enhance capital efficiency, per the filing.The company will oversee rezoning, development, and management, with limited short-term financial impact, while management fees will begin as each stage of investment is completed, the filing added.
$ASX:BLD$ASX:DXS